Pancreatic cancer is highly lethal, with a <5% 5-year survival rate. Therefore, there is a critical need to identify effective therapies to treat pancreatic cancer. Recently, a study identified aberrations in axon guidance genes, including SLIT/ROBO signaling, in pancreatic cancer. There is evidence to suggest that SLIT/ROBO signaling is both upregulated and downregulated in cancer. However, very little is known about how these molecules contribute to carcinogenesis and metastasis. Therefore, there is a critical need to uncover the roles of axon guidance molecules in tumorigenesis and metastasis. Specifically, we aim to uncover the signaling pathways involved in aberrant SLIT/ROBO signaling in pancreatic cancer. To do this we will turn to the model organism C. elegans. Signaling pathways in C. elegans are well conserved, and C. elegans have been previously used to elucidate important molecules in oncogenic signaling pathways. The orthologue of ROBO in C. elegans is
sax-3, which encodes a transmembrane protein involved in axon guidance. To explore the pathways that are important when
sax-3 is upreguated, a gain-of-function transgenic strain expressing activated
sax-3 (myr-
sax-3) in the VD/DD motor neurons will be used. This mutation causes profound axon pathfinding defects. Using RNAi, we knocked down candidate genes in the myr-
sax-3 strain. If these genes are required downstream of activated
sax-3, then the pathfinding defects will be attenuated. To explore the pathways that are important when
sax-3 is downregulated, a deletion strand of
sax-3,
sax-3(
ky123), was used in a synthetic lethal (syn/let) screen to determine which genes are required in the absence of
sax-3. The syn/let screen uses a loss-of-function but viable
sax-3 deletion strain (
sax-3(
ky123)) to test if the loss of any genes involved in a parallel or downstream pathway will result in a synthetic/lethal phenotype. Genes were identified for this screen based on the C. elegans orthologues of human genes that are associated with pancreatic cancer and cancer cell phenotypes such as migration and invasion. Results from the gain-of-function experiment yielded some candidate genes such as
exc-5 and
chw-1. Results from the loss-of-function experiment yielded some candidate genes including
let-60/ras,
ptp-3/lar (leukocyte common antigen related), and
gsk-3 (glycogen synthase kinase 3 beta). It is important to note that oncogenic activating mutations in ras have been found in 90% of pancreatic cancer patients. In the future, the genes identified in this screen will be verified using human pancreatic cancer cells. .